Category Archives: ellaOne®

ellaOne® is contra-indicated for women who:

Are hypersensitive to the active substance or to any of the excipients1

Always refer to the ellaOne® Summary of Product Characteristics if you are in any doubt.

Situations where ellaOne® is not recommended

• Severe asthma treated by oral glucocorticoids1

• Severe hepatic impairment1

• For women taking CYP3A4 inducers1

• For women with long-term use of ritonavir1

• Concomitant use of EC containing levonorgestrel1

• Breastfeeding is not recommended for one week after ellaOne® intake1


Pregnancy registry

With ellaOne®:

  • The majority of adverse events recorded during the complete development programme in 4,718 women were mild or moderate and resolved spontaneously1
  • The most commonly reported adverse reactions were headache, nausea, abdominal pain and dysmenorrhea1
  • The tolerability profile is comparable to levonorgestrel2




ellaOne® effect on the menstrual cycle

Most women had their next menstrual period at the expected time (74.6 % within ±7 days of expected time)1

  • Early period – 6.8% had their period more than 7 days earlier than expected
  • Late period – 18.5% had a delay of more than 7 days1

A minority of women (8.7%) reported intermenstrual bleeding lasting an average of 2.4 days. The majority was reported as spotting (88.2%).1

Only 0.4% reported heavy intermenstrual bleeding1

For full details of adverse events refer to the ellaOne® Summary of Product Characteristics.

Adverse events should be reported. Healthcare professionals are asked to report any suspect adverse events via their national reporting system. Adverse events should also be reported to HRA Pharma at

ellaOne® significantly reduces the risk of unintended pregnancy vs levonorgestrel.1

Two comparative non-inferiority studies showed ellaOne® is at least as effective in preventing pregnancy as levonorgestrel.1,2

A meta-analysis of these two studies comparing ellaOne® with levonorgestrel showed that the risk of pregnancy was significantly reduced with ulipristal acetate compared to levonorgestrel:1


For a woman who comes to you for help, what does this mean?


Her risk of getting pregnant is :

Intake within

  • 24h
  • 72h

of unprotected intercourse

  • With
    no intervention
  • With
  • With
  • arrow
    5.5 %
    5.5 %
  • arrow
    2.3 %
    2.2 %
  • arrow
    0.9 %
    1.4 %

P- value: 0.035

P- value: 0.046

Intake within 24 hours of unprotected intercourse / 72 hours of unprotected intercourse



1. Glasier AF et al. The Lancet 2010; 375: 555-562.
2. Creinin M et al. Obstet Gynecol 2006; 108(5): 1089–1097.
3. Nappi R et al. Eur J Contracept Reprod Health Care 2014; 19(2): 93-101.

Proportion of cycles in which follicular rupture was inhibited for at least 5 days

Ovulation is a result of a surge in luteinising hormone (LH). ellaOne® delays ovulation by inhibiting or delaying the LH surge.1


If the woman is due to ovulate tomorrow or the next day after unprotected sex, when the risk of pregnancy is highest, only ellaOne® can delay ovulation.1


This is when LH has started to surge but has not yet reached the peak. At this time, levonorgestrel will not prevent the follicle from rupturing whereas ellaOne® is highly effective.1

Intake after LH surge, but before peak1



If she is due to ovulate 3 or more days after unprotected intercourse, both ellaOne and levonorgestrel can delay ovulation .1 However, ellaOne® remains more effective in preventing follicle rupture and therefore unintended pregnancy 1.


Intake before LH surge1



If the woman has already ovulated, or is due to ovulate, in the immediate 24 hours of unprotected intercourse, no emergency contraceptive pill help1


This is because the LH has already peaked, meaning the ovulation process is at a point where it cannot be stopped, or has already happened.

This explains why:

• Speed of emergency contraceptive pill intake is critical
• Emergency contraception is not 100% effective

Intake after LH surge 1



ellaOne® can delay ovulation even when it is about to happen (when risk of fertilisation is highest)1





1. Brache V et al. Contraception 2013; 88(5): 611-618.

2. Glasier AF et al. The Lancet 2010; 375: 555-562.



ellaOne® is the most effective emergency contraceptive pill, remember that:


And ellaOne® is now available directly from you, without a prescription.





1. Wilcox AJ et al. BMJ 2000; 321: 1259-62.
2. Wilcox AJ et al. N Engl J Med 1995; 333: 1517-21.
3. Brache V et al. Contraception 2013; 88(5): 611-618.
4. Glasier AF et al. The Lancet 2010; 375: 555-562.

What is ellaOne® ?

  • ellaOne® is an emergency contraceptive pill intended to prevent pregnancy after unprotected sexual intercourse or contraceptive failure2
  • ellaOne® should be taken as soon as possible, but no later than 120 hours (5 days) after UPSI or contraceptive failure2
  • ellaOne® is the most effective oral emergency contraceptive2
  • ellaOne® is for women of reproductive age who want to avoid unintended pregnancy2

How to use ellaOne®

  • The treatment consists of one tablet to be taken orally as soon as possible after UPSI or contraceptive failure2
  • ellaOne® does not offer protection from pregnancy for subsequent acts of unprotected sex. Women should be advised to use a reliable barrier method until her next menstrual period.2
  • The tablet can be taken with or without food2
  • If vomiting occurs within 3 hours of ellaOne® intake, another tablet should be taken2
  • ellaOne® can be taken at any time during the menstrual cycle2



  • ellaOne® is not a regular contraceptive, it is for occasional use only2
  • ellaOne® does not cause abortion4
  • ellaOne® does not protect from sexually transmitted infections5